MedPath

Berberine and Altered Fasting Glucose

Not Applicable
Conditions
Glucose Metabolism Disorders
Registration Number
NCT05031715
Lead Sponsor
Azienda di Servizi alla Persona di Pavia
Brief Summary

The aim of the study was to evaluate the effectiveness of a food supplement, berberine phytosome, which contributes to the control of blood sugar and the improvement of insulin resistance.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
50
Inclusion Criteria
  • Fasting blood glucose range:100-125 mg/dl
Exclusion Criteria
  • Diabetes mellitus

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Changes on carbohydrate profileChanges from baseline carbohydrate profile at 4 weeks and at 8 weeks

Glycated hemoglobin (%)

Changes on insulin resistanceChanges from baseline insulin resistance at 4 weeks and at 8 weeks

Homeostasis Model Assessment (pt), for evaluate insulin resistance if \> 2,4

Secondary Outcome Measures
NameTimeMethod
Changes on body compositionChanges from baseline body composition at 4 weeks and at 8 weeks

Fat mass (g), Fat Free Mass (g), Visceral Adipose Tissue (g)

Changes on lipid profileChanges from baseline lipid profile at 4 weeks and at 8 weeks

Total Cholesterol (mg/dl), High density lipoprotein Cholesterol (mg/dl), Low density lipoprotein Cholesterol (mg/dl), Triglycerides (mg/dl), Apolipoprotein A (mg/dl), Apolipoprotein B (mg/dl)

Changes on Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Changes from baseline Incidence of Treatment-Emergent Adverse Events at 4 weeks and at 8 weeks

Glomerural Filtrate Rate (ml/min)

Changes on anthropometryChanges from baseline anthropometry at 4 weeks and at 8 weeks

Waist circumference (cm)

Trial Locations

Locations (1)

Mariangela Rondanelli

🇮🇹

Pavia, Italy

Mariangela Rondanelli
🇮🇹Pavia, Italy
Mariangela Rondanelli
Contact
mariangela.rondanelli@unipv.it

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.